Sellas Life Sciences Group Inc expected to post breakeven results a share - Earnings Preview

Sellas Life Sciences

12/03/2024 11:02

* Sellas Life Sciences Group Inc  SLS.OQ   SLS.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 14 (estimated) for the period ending December 31 2023
    * The New York City-based  company is expected to report
revenue
of $13 million, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Sellas Life Sciences
Group Inc
is for breakeven results per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Sellas Life
Sciences Group Inc is $7.50​, above​ its last closing price
of $1.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.03        0.03       -0.33     Missed  -1,200
 Jun. 30 2023  -0.34       -0.35      -0.31     Beat    12.7
 Mar. 31 2023  -0.29       -0.29      -0.47     Missed  -61.1​
 Dec. 31 2022  -0.34       -0.32      -0.43     Missed  -34.4
 ​​Sep.        -0.39       -0.39      -0.34     Beat    12.1
 30 2022                                                
 Jun. 30 2022  -0.35       -0.35      -0.41     Missed  -17.1​
 Mar. 31 2022  -0.38       -0.38      -1.05     Missed  -176.3
 Dec. 31 2021  -0.45       -0.41      -0.42     Missed  -2.4
 This summary was machine generated March 12 at 11:02 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)